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Functionalized Cyclopentenes
Fluorine-Containing Functionalized Cyclopentene Scaffolds
Through Ring Contraction and Deoxofluorination of Various
Substituted Cyclohexenes
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Ferenc Fülöp,*[a,b] and Loránd Kiss*[a]
Abstract: The fluorination of some highly-functionalized cyclo-
pentene derivatives, obtained from various substituted cyclo-
hexenes through a ring-opening/ring-contraction procedure,
has been investigated. The transformations were found to be
Introduction
Late-stage fluorination with various commercially available nu-
cleophilic reagents is a common method for the introduction
of fluorine into organic molecules, and thus to access various
fluorine-containing molecular entities.[1] Late-stage fluorination
based on hydroxy–fluorine or carbonyl–difluorine exchange is
considered to be a relatively simple synthetic approach. In cer-
tain circumstances, these types of transformations have been
found to be highly substrate dependent; the presence of vari-
ous functional groups strongly determined and directed the
outcome of the deoxofluorination reactions. Some deoxofluori-
nations proceed with high chemoselectivity; nucleophilic fluori-
nating agents, such as Deoxofluor [bis(2-methoxyethyl)amino-
sulfur trifluoride], DAST (diethylaminosulfur trifluoride), or Xtal-
Fluor [(diethylamino)difluorosulfonium tetrafluoroborate], are
able to transform the hydroxy or oxo moieties of various highly
functionalized substrates with chemodiscrimination between
these groups. Besides the expected products, however, such
reactions may often produce some surprising fluorinated or
non-fluorinated structures; this is particularly true for com-
pounds with multiple functional groups and stereogenic cen-
ters.[1,2] In view of the high pharmaceutical relevance of fluorin-
ated organic molecules,[3] fluorination techniques, including
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highly substrate dependent, and led to the formation of various
functionalized alicyclic compounds or heterocycles containing
allyl difluoride or vinyl fluoride moieties.
late-stage fluorination protocols such as oxo–difluorine inter-
conversion, especially of highly functionalized compounds, are
still considered to be an interesting challenge for synthetic
chemists. Therefore, in order to investigate the chemical behav-
ior of some polyfunctionalized substrates under deoxofluorina-
tion conditions, we selected some functionalized alicyclic com-
pounds possessing carboxylate and amide or carbamate
groups. The use of -amino acid derivatives (as promising bio-
logically active derivatives)[4] as well as some alicyclic esters and
N-protected compounds allowed us to study both the inde-
pendent and synergistic behavior of these moieties.
Results and Discussion
Taking into consideration some unexpected findings from our
earlier experimental investigations into the late-stage fluorin-
ation of various functionalized alicyclic compounds,[2] in this
project we aimed to continue to explore the chemical behavior
of some variously polysubstituted six-membered carbocycles
through oxidative ring-opening/ring-contraction/fluorination.
Because of the high biological relevance of -amino acids,[4] we
first selected as model compounds for our experiments some
stereo- and regioisomers of cyclohexene -amino acids. Thus,
cis- and trans-2-aminocyclohexenecarboxylic acids (±)-1 and
(±)-5 were first converted by known procedures into the
corresponding dihydroxylated amino esters (±)-2 and (±)-6
(Scheme 1).[5]
The aldol reaction of various substituted scaffolds (e.g.,
amino, nitro, halogen, hydroxy, and other substituted com-
pounds, as well as carbonyl derivatives, and some oxo esters)
and its intramolecular asymmetric version[6] are well-known
fundamental approaches for the formation of molecules with
diverse structures containing an α,-unsaturated carbonyl moi-
ety.
Six-membered-ring diol derivatives (±)-2 and (±)-6 were sub-
mitted to oxidative ring opening with NaIO4 followed by intra-
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Scheme 1.
molecular aldol reactions in the presence of morpholinium tri-
fluoroacetate (TFA). These transformations gave the corre-
sponding five-membered-ring regioisomeric aldols (±)-3 and
(±)-4 (for the cis derivative) and (±)-7 and (±)-8 (for the trans
isomer) in an unselective manner as mixtures, with 2:1 and 1:1
ratios, respectively. These five-membered-ring formyl-substi-
tuted -amino esters might be considered to be valuable com-
pounds for organic transformations, For example, the five-mem-
bered-ring amino acids cispentacin and icofungipen are known
to act as antibacterial agents.[4a]
Scheme 2.
Scheme 3.
Eur. J. Org. Chem. 2018, 3735–3742 www.eurjoc.org © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim3736
Unfortunately, all our attempts to separate the formyl-substi-
tuted cyclopentene amino ester regioisomers shown in
Scheme 1 failed. This failure, however, did not discourage us
from continuing our investigation using cis-2-aminocyclohex-3-
ene carboxylic acid (±)-9, an isomer of (±)-1 and (±)-5. Com-
pound (±)-9 was converted into the corresponding diol deriva-
tive (±)-10 by using a literature procedure.[5] Vicinal diol (±)-10,
in turn, was subjected to NaIO4-mediated oxidative ring open-
ing, followed by intramolecular ring closure induced by the
morpholine salt. In contrast to our results presented in
Scheme 1, cyclization of the unstable diformyl derivative T3
proceeded with complete selectivity to give unsaturated alde-
hyde derivative (±)-11 as a single product (Scheme 2).
The cyclization process leading to (±)-11 can be interpreted
as shown in Scheme 3. Intramolecular hydrogen bonding in the
transition state is probably responsible for the selectivity of the
reaction. A stable structure may arise through a hydrogen-
bonding interaction between the amide NH and the enamine
nitrogen lone pair (formed in the reaction of morpholine with
the formyl group located furthest from the amide). On the other
hand, an enamine intermediate resulting from the reaction of
morpholine with the formyl moiety close to the amide would
give an unfavorable structure (Figure 1).
Full Paper
Figure 1. Intramolecular hydrogen bonding in structure of intermediate T5
Next, cyclopentene acylamino ester (±)-11, which has an α,-
unsaturated aldehyde moiety with two electrophilic centers for
1,2- or 1,4-addition, was subjected to fluorination under various
reaction conditions, all of which gave practically the same re-
sult. The experiments were carried out systematically, varying
the reaction solvent (CH2Cl2, PhMe, THF), the nucleophilic fluori-
nating agent (Deoxofluor, DAST), and the reaction temperature
(0 °C, room temperature). Unfortunately, no significant effect on
either the yield or the selectivity of the reaction was observed.
Two products were formed in an almost 1:1 ratio; they were
separated by chromatography, isolated, and characterized by
NMR spectroscopy and/or X-ray crystallography. One of the
products was identified as the expected difluorinated com-
pound (±)-12 (Figure 2 and Scheme 2). The other product, (±)-
13, somewhat surprisingly, was identified as a heterocyclic com-
Figure 2. X-ray structure of (±)-12.
Scheme 4.
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pound containing a vinyl fluoride moiety. The formation of
product (±)-12, with its allyl difluoride moiety, is unambiguous;
the formation of (±)-13 might be the result of an intramolecular
attack of the amide oxygen atom on the electrophilic sp2 car-
bon atom of intermediate T7. This intermediate contains a
good leaving group formed from the formyl group and Deoxo-
fluor, and reacts Z-selectively to give an oxazoline derivative
with a vinyl fluoride moiety (Scheme 4). The structure of (±)-13
was determined on the basis of 2D NMR spectroscopic analysis.
Fluorovinylation reactions and the resulting fluorovinyl com-
pounds — important elements in many biologically relevant
compounds — have received special attention in synthetic or-
ganic and pharmaceutical chemistry.[7,8a] In addition, the allyl
difluoride motif is found in a series of pharmaceuticals and
agrochemicals.[8] In view of the importance of these fluorinated
derivatives, we found it interesting to continue our investiga-
tion into the intramolecular cyclization and subsequent fluorin-
ation protocol using other structures. Diol derivative (±)-14, a
stereoisomer of (±)-10 accessed from (±)-9, gave formyl-substi-
tuted cyclic amino ester (±)-15 upon treatment with NaIO4. This
reaction proceeded through ring opening to give unstable
dialdehyde derivative (±)-T8, followed by intramolecular con-
densation (Scheme 5). When compound (±)-15 was treated
with Deoxofluor, analogously to its cis counterpart, compounds
(±)-17 and (±)-16 were formed in a nearly 1.3:1 ratio. These
were separated by column chromatography; the minor product
was identified as difluorinated compound (±)-16 (Figure 3), and
the major product as cyclized oxazoline derivative (±)-17.
The results described above on oxidative ring-opening/intra-
molecular aldol reaction/fluorination reactions carried out with
some cyclic -amino acid derivatives motivated us to continue
these investigations with other six-membered ring systems. We
chose compounds bearing either ester or protected amino
groups, which allowed us to test the influence of each of these
functional groups on the outcome of the reaction.
First we tested dihydroxylated diester (±)-18.[2e] This sym-
metrical molecule gave formyl-substituted derivative (±)-19 as
a single product as the result of a ring-opening/intramolecular
cyclization process. Fluorination of this diester with DAST or
Deoxofluor under various conditions gave allyl difluoride deriv-
ative (±)-20 as the sole product. The highest yield was obtained
with DAST in CH2Cl2 at room temperature (Scheme 6). The se-




Figure 3. X-ray structure of (±)-16.
We expected that the evaluation of six-membered-ring
benzyl cyclohexenecarboxylate (±)-21 would give more inter-
esting results.[9] Dihydroxylation of (±)-21 gave an inseparable
mixture of cis and trans diols (±)-22. Since both isomers would
lead to the same dialdehyde, this mixture was used in the oxid-
ative ring-opening/cyclization step. According to our expecta-
tions, the intramolecular aldol reaction gave two formylated de-
rivatives, which, in turn, were separated and identified as com-
pounds (±)-23 (minor) and (±)-24 (major). Fluorination of (±)-
23 under various conditions with Deoxofluor in CH2Cl2 yielded
a single product, the corresponding geminal difluorinated com-
pound (±)-25 (Scheme 7). Unfortunately, all attempts at fluorin-
ation of the major isomer (±)-24 under various conditions
failed, and only decomposed materials were detected.
Scheme 6.
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Scheme 7. NMO = N-methylmorpholine N-oxide.
Next, we carried out related experiments using amino-substi-
tuted cyclohexane derivative (±)-26.[10] Oxidative ring-opening/
aldol cyclization of (±)-26, again, gave two products in an ap-
proximately 1:1 ratio.
Compounds (±)-27 and (±)-28 could be separated and char-
acterized. Interestingly, when these compounds were subjected
to fluorination, no intramolecular ring closure with internal as-
sistance of the carbamate was observed, in contrast to the reac-
tions of (±)-11 and (±)-15. Instead, only geminal difluorinated
products (±)-29 and (±)-30 were detected and isolated. The
highest yields, again, were obtained through the use of DAST
in CH2Cl2 at room temperature (Scheme 8).
It is noteworthy that substituted five-membered ring sys-
tems are, in general, more expensive than their six-membered
analogs. Consequently, functionalized cyclopentene derivatives
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Scheme 8. Cbz = benzyloxycarbonyl.
synthesized according to Schemes 6, 7, and 8 might be re-
garded as valuable compounds for a wide variety of further
transformations.
Finally, the behavior of a bicyclic system was also investi-
gated. Dihydroxylation of imide (±)-31 proceeded cis-selectively
and resulted in diol (±)-32. Ring-opening/cyclization reactions
of this symmetrical derivative then gave compound (±)-33 as a
single formyl-substituted product. Fluorination of (±)-33 gave a




The synthesis of various fluorine-containing molecular scaffolds
has been achieved starting from readily available functionalized
six-membered carbocycles. This approach involves oxidative
ring-opening/ring-contraction/fluorination sequences, and
leads to molecules containing allyl or vinyl fluoride moieties.
Ring closure through intramolecular aldol reactions was found
to be substrate dependent, and gave various functionalized
α,-unsaturated aldehyde systems. Fluorination of these com-
pounds then gave either 1,2- or 1,4-addition products. Investi-
gations into the extension of these methods to give the
enantiomers, and also into the regioselectivity of the intra-
molecular aldol reactions on various systems, are currently un-
derway in our laboratory.
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Furthermore, we are also currently investigating related
transformations with other nucleophilic reagents and on other
highly functionalized cycloalkane substrates.
Experimental Section
General Procedure for Ring-Contraction Reactions — Synthesis
of Formyl-Substituted Cyclopentene Amino Esters: NaIO4
(279 mg, 1.3 mmol) was added to a solution of the diol derivative
(200 mg, 0.65 mmol) in THF/H2O (10:1 v/v; 11 mL). The reaction
mixture was stirred for 1 h at room temperature under an Ar atmos-
phere, resulting in the corresponding diformyl derivative. Water
(20 mL) was then added, and the mixture was extracted with CH2Cl2
(2 × 15 mL). The combined organic phases were dried with Na2SO4,
and filtered, and the solvents were evaporated in vacuo.
The resulting unstable dialdehyde was dissolved in dry THF (10 mL),
and then morpholinium TFA salt (131 mg, 0.65 mmol) was added.
The mixture was stirred for 1 h at room temperature, then it was
washed with water (2 × 15 mL). The organic phase was dried with
Na2SO4, and filtered, and the solvent was evaporated under re-
duced pressure. The crude mixture was purified by column chroma-
tography on silica gel (n-hexane/EtOAc) to give the corresponding
α,-unsaturated aldehyde derivative.
General Procedure for the Fluorination of Formyl-Substituted
Cyclopentene Amino Esters: DAST or Deoxofluor (see text) was
added to a solution of the formyl derivative (144 mg, 0.5 mmol) in
CH2Cl2 (10 mL) at 20 °C, and the mixture was stirred at this tempera-
ture for 4 h. The mixture was then diluted with CH2Cl2 (20 mL),
washed with saturated NaHCO3 solution (2 × 15 mL), dried
(Na2SO4), and concentrated. The crude residue was purified by col-
umn chromatography on silica gel.
General Procedure for Dihydroxylation: OsO4 (2 % in tBuOH;
0.3 mL), and NMO (N-methylmorpholine N-oxide; 1.2 equiv.) were
added to a stirred solution of substituted cycloalkene (10 mmol) in
acetone (30 mL) and water (3 mL), and the resulting mixture was
stirred at room temp. for the time given in the text. When the
reaction was complete, the mixture was treated with saturated
aqueous Na2SO3 solution, and then extracted with CH2Cl2 (3 ×
30 mL). The combined organic layers were dried with Na2SO4, and
filtered, and the solvent was evaporated under reduced pressure.
The crude product was purified by column chromatography on sil-
ica gel (n-hexane/EtOAc or n-hexane/acetone).
Ethyl (1R*,2S*)-2-Benzamido-4-formylcyclopent-3-enecarboxy-
late [(±)-11]: White solid (38 % over two steps). M.p. 85–88 °C. Rf =
0.40 (n-hexane/EtOAc, 1:2). 1H NMR (400 MHz, CDCl3): δ = 1.24 (t,
J = 7.12 Hz, 3 H, CH3), 2.85–3.10 (m, 2 H, CH2), 3.57–3.68 (m, 1 H, 1-
H), 4.08–4.24 (m, 2 H, OCH2), 5.77–5.87 (m, 1 H, 2-H), 6.74–6.81 (m,
1 H, 3-H), 7.12 (br. s, 1 H, N-H), 7.42–7.60 (m, 3 H, Ar-H), 7.75–7.84
(m, 2 H, Ar-H), 9.87 (s, 1 H, CHO) ppm. 13C NMR (125 MHz, CDCl3):
δ = 14.1, 31.9, 45.3, 55.8, 61.4, 127.0, 128.6, 132.0, 133.6, 146.4,
147.8, 166.6, 173.2, 189.1 ppm. C16H17NO4 (287.31): calcd. C 66.89,
H 5.96, N 4.88; found C 66.58, H 5.60, N 4.57.
Ethyl (1S*,2S*)-2-Benzamido-4-formylcyclopent-3-enecarboxy-
late [(±)-15]: White solid (42 % over two steps). M.p. 141–143 °C.
Rf = 0.36 (n-hexane/EtOAc, 1:2). 1H NMR (400 MHz, CDCl3): δ = 1.26
(t, J = 7.14 Hz, 3 H, CH3), 2.73–2.84 (m, 1 H, CH2), 2.98–3.08 (m, 1 H,
CH2), 3.15–3.26 (m, 1 H, 1-H), 4.15–4.25 (m, 2 H, OCH2), 5.48–5.57
(m, 1 H, 2-H), 6.60 (br. s, 1 H, N-H), 6.74–6.80 (m, 1 H, 3-H), 7.39–
7.57 (m, 3 H, Ar-H), 7.74–7.83 (m, 2 H, Ar-H), 9.79 (s, 1 H, CHO) ppm.
13C NMR (100 MHz, CDCl3): δ = 14.5, 31.8, 50.2, 60.2, 61.8, 127.4,
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129.1, 132.4, 134.1, 145.7, 148.6, 167.7, 173.5, 189.4 ppm. C16H17NO4
(287.31): calcd. C 66.89, H 5.96, N 4.88; found C 67.19, H 5.62, N
4.55.
Ethyl (1R*,2S*)-2-Benzamido-4-(difluoromethyl)cyclopent-3-en-
ecarboxylate [(±)-12]: White solid (36 %). M.p. 85–86 °C. Rf = 0.50
(n-hexane/EtOAc, 2:1). 1H NMR (400 MHz, CDCl3): δ = 1.18 (t, J =
7.14 Hz, 3 H, CH3), 2.71–2.82 (m, 1 H, CH2), 2.95–3.07 (m, 1 H, CH2),
3.55–3.65 (m, 1 H, 1-H), 4.02–4.18 (m, 2 H, OCH2), 5.61–5.72 (m, 1
H, 2-H), 6.00–6.07 (m, 1 H, 3-H), 6.10–6.43 (t, J = 55.3 Hz, 1 H, CHF2),
6.70 (br. s, 1 H, N-H), 7.38–7.54 (m, 3 H, Ar-H), 7.69–7.78 (m, 2 H, Ar-
H) ppm. 13C NMR (125 MHz, CDCl3): δ = 14.1, 32.0, 45.6, 55.5, 61.3,
110.1 and 112.0 and 113.8 (1J = 235.3 Hz), 127.0, 128.7, 131.6 and
131.7 and 131.8 (3J = 8.7 Hz), 131.8, 133.9, 139.8 and 140.0 and
140.2 (2J = 23.8 Hz), 166.6, 172.9 ppm. 19F NMR (100 MHz, CDCl3):
δ = –116.7 (d, 2JH,F = 54.8 Hz), –116.8 (d, 2JH,F = 55.1 Hz) ppm. MS
(ESI+): m/z = 310 [M + 1]. C16H17F2NO3 (309.31): calcd. C 62.13, H
5.54, N 4.53; found C 62.49, H 5.20, N 4.18.
Ethyl (3aR*,4R*,6aS*,Z)-6-(Fluoromethylene)-2-phenyl-4,5,6,6a-
tetrahydro-3aH-cyclopenta[d]oxazole-4-carboxylate [(±)-13]:
White solid (38 %). M.p. 60–62 °C. Rf = 0.55 (n-hexane/EtOAc, 2:1).
1H NMR (400 MHz, CDCl3): δ = 1.37 (t, J = 7.12 Hz, 3 H, CH3), 2.49–
2.64 (m, 1 H, CH2), 2.79–2.90 (m, 1 H, CH2), 3.06–3.18 (m, 1 H, 4-H),
4.25–4.37 (m, 2 H, OCH2), 5.04–5.13 (m, 1 H, 3a-H), 5.34–5.42 (m, 1
H, 6a-H), 6.78–7.05 (dd, J = 82.05, J = 2.54 Hz, 1 H, HCF), 7.36–7.54
(m, 3 H, Ar-H), 7.87–7.98 (m, 2 H, Ar-H) ppm. 13C NMR (100 MHz,
CDCl3): δ = 14.7, 25.5, 49.5, 61.2, 73.5, 82.4 and 82.5 (3J = 11.4 Hz),
123.1 and 123.2 (2J = 8.8 Hz), 127.5, 128.7, 129.0, 132.0, 146.4 and
149.0 (1J = 262.7 Hz), 164.9, 170.9 ppm. 19F NMR (100 MHz, CDCl3):
δ = –124.4 (d, 2J = 82.0 Hz) ppm. MS (ESI+): m/z = 291 [M + 1].
C16H16FNO3 (289.31): calcd. C 66.43, H 5.57, N 4.84; found C 66.09,
H 5.21, N 5.19.
Ethyl (1S*,2S*)-2-Benzamido-4-(difluoromethyl)cyclopent-3-en-
ecarboxylate [(±)-16]: White solid (30 %). M.p. 83–85 °C. Rf = 0.45
(n-hexane/EtOAc, 2:1). 1H NMR (400 MHz, CDCl3): δ = 1.27 (t, J =
7.12 Hz, 3 H, CH3), 2.77–2.99 (m, 2 H, CH2), 3.05–3.15 (m, 1 H, 1-H),
4.12–4.27 (m, 2 H, OCH2), 5.45–5.55 (m, 1 H, 2-H), 6.02–6.09 (m, 1
H, 3-H), 6.09–6.41 (t, J = 55.36 Hz, 1 H, CHF2, and brs, 1 H, N-H),
7.39–7.57 (m, 3 H, Ar-H), 7.71–7.82 (m, 2 H, Ar-H) ppm. 13C NMR
(125 MHz, CDCl3): δ = 14.1, 32.0, 50.3, 59.4, 61.3, 110.0 and 111.9
and 113.8 (1J = 235.2 Hz), 127.0, 128.7, 131.8, 132.0 and 132.1 and
132.2 (3J = 8.9 Hz), 133.9, 138.7 and 138.9 and 139.0 (2J = 23.8 Hz),
167.0, 173.1 ppm. 19F NMR (100 MHz, CDCl3): δ = –116.7 (d, 2JH,F =
54.8 Hz), –116.9 (d, 2JH,F = 55.6 Hz) ppm. MS (ESI+): m/z = 310 [M +
1]. C16H17F2NO3 (309.31): calcd. C 62.13, H 5.54, N 4.53; found C
61.81, H 5.19, N 4.19.
Ethyl (3aR*,4S*,6aS*,Z)-6-(Fluoromethylene)-2-phenyl-4,5,6,6a-
tetrahydro-3aH-cyclopenta[d]oxazole-4-carboxylate [(±)-17]:
Yellow oil (41 %). Rf = 0.50 (n-hexane/EtOAc, 2:1). 1H NMR (400 MHz,
CDCl3): δ = 1.27 (t, J = 7.12 Hz, 3 H, CH3), 2.47–2.60 (m, 1 H, CH2),
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2.87–2.97 (m, 1 H, CH2), 3.21–3.30 (m, 1 H, 4-H), 4.12–4.23 (m, 2 H,
OCH2), 5.01–5.09 (m, 1 H, 3a-H), 5.40–5.47 (m, 1 H, 6a-H), 6.78–7.05
(d, J = 82.03 Hz, 1 H, HCF), 7.36–7.53 (m, 3 H, Ar-H), 7.88–7.96 (m,
2 H, Ar-H) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.5, 27.9, 50.5,
61.5, 74.7, 82.9 and 83.1 (3J = 10.9 Hz), 123.0 and 123.1 (2J = 9.0 Hz),
127.5, 128.8, 128.8. 132.1, 146.8 and 149.4 (J = 262.6 Hz), 164.8,
173.8 ppm. 19F NMR (100 MHz, CDCl3): δ = –124.1 (d, 2JH,F = 82.1 Hz)
ppm. MS (ESI+): m/z = 291 [M + 1]. C16H16FNO3 (289.31): calcd. C
66.43, H 5.57, N 4.84; found C 66.80, H 5.23, N 4.50.
(1S*,2S*)-Dimethyl 3-Formylcyclopent-3-ene-1,2-dicarboxylate
[(±)-19]: Pale yellow solid (72 %). M.p. 30–32 °C. Rf = 0.46 (n-hexane/
EtOAc, 1:1). 1H NMR (500 MHz, CDCl3): δ = 2.89 (ddd, 2J = 19.20,
3J = 8.90, 3J = 2.95 Hz, 1 H, 5-H), 3.26 (ddt, 2J = 19.20, 3J = 8.85,
3J = 2.25 Hz, 1 H, 5-H), 3.52 (q, J = 9.03 Hz, 1 H, 1-H), 3.68 (s, 3 H,
OCH3), 3.71 (s, 3 H, OCH3), 4.07–4.12 (m, 1 H, 2-H), 7.02–7.06 (m, 1
H, 4-H), 9.71 (s, 1 H, CHO) ppm. 13C NMR (125 MHz, CDCl3): δ = 35.6,
46.5, 49.2, 52.2, 52.3, 144.2, 152.9, 171.7, 172.0, 187.7 ppm. MS (ESI+):
m/z = 213, [M + 1]. C10H12O5 (212.20): calcd. C 56.60, H 5.70; found
C 56.94, H 5.97.
(1S*,2S*)-Dimethyl 3-(Difluoromethyl)cyclopent-3-ene-1,2-di-
carboxylate [(±)-20]: Pale yellow oil (46 %). Rf = 0.43 (n-hexane/
EtOAc, 3:1). 1H NMR (400 MHz, CDCl3): δ = 2.64–2.78 (m, 1 H, 5-H),
2.99–3.13 (m, 1 H, 5-H), 3.49 (q, J = 8.99 Hz, 1 H, 2-H), 3.69 (s, 3 H,
OCH3), 3.70 (s, 3 H, OCH3), 3.90–3.96 (m, 1 H, 1-H), 6.09–6.41 (t, J =
55.44 Hz, 1 H, CHF2), 6.27–6.32 (m, 1 H, 4-H) ppm. 13C NMR
(125 MHz, CDCl3): δ = 34.2, 46.9, 50.0 and 50.0 (3J = 1.27 Hz), 52.1,
52.3, 110.1 and 112.0 and 113.9 (1J = 235.58 Hz), 135.0 and 135.2
and 135.4 (2J = 23.27 Hz), 136.5 and 136.5 and 136.6 (3J = 8.40 Hz),
172.0, 172.3 ppm. 19F NMR (376 MHz, CDCl3): δ = –114.55 (dd, 2JF,F =
302.57, 2JH,F = 55.10 Hz), –117.93 (dd, 2JF,F = 303.27, 2JH,F = 55.72 Hz)
ppm. C10H12F2O4 (234.20): calcd. C 51.28, H 5.16; found C 50.98, H
4.78.
Benzyl 3-Formylcyclopent-3-enecarboxylate [(±)-24]: Pale yellow
oil (46 %). Rf = 0.58 (n-hexane/EtOAc, 2:1). 1H NMR (400 MHz, CDCl3):
δ = 2.78–3.08 (m, 4 H, 2-H, 5-H), 3.24–3.40 (m, 1 H, 1-H), 5.15 (s, 2
H, benzylic CH2), 6.74–6.80 (m, 1 H, 4-H), 7.30–7.41 (m, 5 H, CH-Ar),
9.75 (s, 1 H, CHO) ppm. 13C NMR (100 MHz, CDCl3): δ = 32.5, 36.9,
41.3, 66.7, 128.2, 128.4, 128.6, 135.7, 145.7, 149.9, 174.6, 189.1 ppm.
MS (ESI+): m/z = 231 [M + 1]. C14H14O3 (230.26): calcd. C 73.03, H
6.13; found C 72.75, H 5.77.
Benzyl 2-Formylcyclopent-2-enecarboxylate [(±)-23]: Pale yellow
oil (27 %). Rf = 0.49 (n-hexane/EtOAc, 2:1). 1H NMR (400 MHz, CDCl3):
δ = 2.11–2.23 (m, 1 H, 5-H), 2.30–2.43 (m, 1 H, 5-H), 2.56–2.69 (m, 1
H, 4-H), 2.70–2.83 (m, 1 H, 4-H), 3.78–3.87 (m, 1 H, 1-H), 5.14 (s, 2 H,
benzylic CH2), 6.98–7.04 (m, 1 H, 3-H), 7.28–7.40 (m, 5 H, CH-Ar),
9.77 (s, 1 H, CHO) ppm. 13C NMR (100 MHz, CDCl3): δ = 28.6, 33.1,
47.1, 66.7, 128.1, 128.2, 128.5, 135.9, 145.5, 154.4, 173.7, 188.3 ppm.
MS (ESI+): m/z = 253 [M + Na]. C14H14O3 (230.26): calcd. C 73.03, H
6.13; found C 73.34, H 5.79.
Benzyl 2-(Difluoromethyl)cyclopent-2-enecarboxylate [(±)-25]:
Pale yellow oil (40 %). Rf = 0.50 (n-hexane/EtOAc, 8:1). 1H NMR
(400 MHz, CDCl3): δ = 2.20–2.37 (m, 2 H, 5-H), 2.39–2.52 (m, 1 H, 4-
H), 2.54–2.69 (m, 1 H, 4-H), 3.70–3.79 (m, 1 H, 1-H), 5.09–5.19 (m, 2
H, benzylic CH2), 6.15–6.47 (t, J = 55.98 Hz, 1 H, CHF2), 6.24–6.30
(m, 1 H, and 3-H), 7.30–7.43 (m, 5 H, CH-Ar) ppm. 13C NMR (100 MHz,
CDCl3): δ = 28.3, 31.7, 48.4, 66.8, 110.2 and 112.5 and 114.8 (1J =
235.89 Hz), 128.2, 128.3, 128.6, 135.7, 137.1 and 137.2 and 137.2
(3J = 7.96 Hz), 173.6 ppm. MS (ESI+): m/z = 275 [M + Na]. 19F NMR
(376 MHz, CDCl3): δ = –114.30 (dd, 2JF,F = 298.98, 2JH,F = 55.12 Hz),
–117.64 (dd, 2JF,F = 299.02, 2JH,F = 55.99 Hz) ppm. C14H14F2O2
(252.26): calcd. C 66.66, H 5.59; found C 66.99, H 5.95.
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Benzyl (3-Formylcyclopent-3-en-1-yl)carbamate [(±)-27]: Pale
yellow oil (25 %). Rf = 0.47 (n-hexane/EtOAc, 1:1). 1H NMR (400 MHz,
CDCl3): δ = 2.37–2.48 (dd, J = 16.83, J = 2.70 Hz, 1 H, 5-H), 2.48–
2.64 (d, J = 19.53 Hz, 1 H, 2-H), 2.87–2.99 (dd, J = 17.15, J = 7.82 Hz,
1 H, 5-H), 2.99–3.14 (dd, J = 19.21, J = 6.08 Hz, 1 H, 2-H), 4.36–4.57
(m, 1 H, 1-H), 4.84–5.01 (m, 1 H, NH), 5.10 (s, 2 H, benzylic CH2),
6.76–6.86 (m, 1 H, 4-H), 7.28–7.47 (m, 5 H, CH-Ar), 9.74 (s, 1 H, CHO)
ppm. 13C NMR (125 MHz, CDCl3): δ = 36.5, 41.8, 50.9, 67.2, 128.6,
128.7, 129.0, 136.7, 145.7, 149.9, 156.2, 189.7 ppm. MS (ESI+): m/z =
246 [M + 1]. C14H15NO3 (245.28): calcd. C 68.56, H 6.16, N 5.71;
found C 68.88, H 6.45, N 5.38.
Benzyl (2-Formylcyclopent-2-en-1-yl)carbamate [(±)-28]: Pale
yellow solid (23 %). M.p. 57–62 °C. Rf = 0.38 (n-hexane/EtOAc, 1:1).
1H NMR (400 MHz, CDCl3): δ = 1.87–2.05 (m, 1 H, 5-H), 2.41–2.63
(m, 2 H, 4-H, 5-H), 2.65–2.84 (m, 1 H, 4-H), 4.85–4.97 (m, 1 H, 1-H),
4.99–5.21 (m, 3 H, benzylic CH2 and NH), 6.99–7.10 (m, 1 H, 3-H),
7.24–7.45 (m, 5 H, CH-Ar), 9.79 (s, 1 H, CHO) ppm. 13C NMR
(100 MHz, CDCl3): δ = 32.1, 32.6, 54.9, 67.1, 128.5, 128.9, 136.9,
145.7, 156.0, 156.3, 189.2 ppm. MS (ESI+): m/z = 246 [M + 1].
C14H15NO3 (245.28): calcd. C 68.56, H 6.16, N 5.71; found C 68.92, H
5.85, N 5.41.
Benzyl [2-(Difluoromethyl)cyclopent-2-en-1-yl]carbamate [(±)-
30]: White solid (46 %). M.p. 48–53 °C. Rf = 0.64 (n-hexane/EtOAc,
2:1). 1H NMR (400 MHz, CDCl3): δ = 1.73–1.88 (m, 1 H, 5-H), 2.29–
2.61 (m, 3 H, 4-H, 5-H), 4.78–5.01 (m, 2 H, 1-H, NH), 5.04–5.23 (m, 2
H, benzylic CH2), 6.08–6.43 (t, J = 55.30 Hz, 1 H, CHF2), 6.27–6.33
(m, 1 H, and 3-H), 7.27–7.46 (m, 5 H, CH-Ar) ppm. 13C NMR (100 MHz,
CDCl3): δ = 30.5, 32.9, 56.0, 67.2, 110.5 and 112.9 and 115.2 (1J =
235.41 Hz), 128.5, 128.5, 128.9, 136.9, 138.0 and 138.0 and 138.1
(3J = 7.79 Hz), 156.1 ppm. 19F NMR (376 MHz, CDCl3): δ = –113.07
(dd, 2JF,F = 303.87, 2JH,F = 55.61 Hz), –116.04 (dd, 2JF,F = 303.23,
2JH,F = 56.10 Hz) ppm. MS (ESI+): m/z = 268 [M + 1]. C14H15F2NO2
(267.27): calcd. C 62.91, H 5.66, N 5.24; found C 63.20, H 5.31, N
5.51.
Benzyl [3-(Difluoromethyl)cyclopent-3-en-1-yl]carbamate [(±)-
29]: Colorless oil (20 %). Rf = 0.39 (n-hexane/acetone, 4:1). 1H NMR
(500 MHz, CDCl3): δ = 2.27–2.40 (m, 2 H, 2-H, 5-H), 2.79–2.94 (m, 2
H, 2-H, 5-H), 4.40–4.51 (m, 1 H, 1-H), 4.90–5.03 (m, 1 H, NH), 5.09 (s,
2 H, benzylic CH2), 5.96–6.04 (m, 1 H, 4-H), 6.04–6.36 (t, J = 55.70 Hz,
1 H, CHF2), 7.28–7.41 (m, 5 H, CH-Ar) ppm. 13C NMR (125 MHz,
CDCl3): δ = 29.7, 36.9, 40.2, 50.5, 66.8, 110.7 and 112.6 and 114.5
(1J = 235.57 Hz), 128.2, 128.2, 128.6, 131.4 and 131.5 and 131.6 (3J =
9.13 Hz), 136.0 and 136.2 (2J = 23.92 Hz), 136.4, 155.8 ppm. 19F NMR
(471 MHz, CDCl3): δ = –115.48 (d, 2JH,F = 55.77 Hz) ppm. MS (ESI+):
m/z = 268 [M + 1]. C14H15F2NO2 (267.27): calcd. C 62.91, H 5.66, N
5.24; found C 63.21, H 6.02, N 5.55.
(3aR*,5R*,6S*,7aS*)-2-Benzyl-5,6-dihydroxyhexahydro-1H-iso-
indole-1,3(2H)-dione [(±)-32]: White solid (69 %). M.p. 135–138 °C.
Rf = 0.29 (n-hexane/acetone, 1:1). 1H NMR (500 MHz, [D6]DMSO):
δ = 1.57–1.66 (m, 2 H, 4-H, 7-H), 1.86–1.96 (m, 2 H, 4-H, 7-H), 3.03–
3.10 (m, 2 H, 3-Ha and 7-Ha), 3.42–3.49 (m, 2 H, 5-H, 6-H), 4.52 (s, 2
H, benzylic CH2), 4.67 (d, J = 3.95 Hz, 2 H, OH), 7.18–7.34 (m, 5 H,
CH-Ar) ppm. 13C NMR (125 MHz, [D6]DMSO): δ = 27.4, 36.8, 40.5,
66.5, 126.7, 126.8, 127.9, 135.8, 178.7 ppm. MS (ESI+): m/z = 276 [M
+ 1]. C15H17NO4 (275.30): calcd. C 65.44, H 6.22, N 5.09; found C
65.79, H 6.48, N 5.34.
(3aS*,6aS*)-2-Benzyl-1,3-dioxo-1,2,3,3a,6,6a-hexahydrocyclo-
penta[c]pyrrole-4-carbaldehyde [(±)-33]: Pale yellow solid (45 %).
M.p. 115–132 °C. R f = 0.38 (n-hexane/acetone, 3:2). 1H NMR
(500 MHz, [D6]DMSO): δ = 2.77–2.86 (m, 1 H, 6-H), 3.02–3.12 (m, 1
H, 6-H), 3.67–3.75 (m, 1 H, 6-Ha), 4.22–4.28 (m, 1 H, 3-Ha), 4.51 (s, 2
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H, benzylic CH2), 7.08–7.13 (m, 1 H, 5-H), 7.15–7.20 (m, 2 H, CH-Ar),
7.22–7.34 (m, 3 H, CH-Ar), 9.75 (s, 1 H, CHO) ppm. 13C NMR
(125 MHz, [D6]DMSO): δ = 36.1, 41.9, 43.5, 50.4, 127.7, 127.9, 129.0,
136.5, 142.0, 153.9, 175.7, 179.3, 188.7 ppm. MS (ESI+): m/z = 256
[M + 1]. C15H13NO3 (255.27): calcd. C 70.58, H 5.13, N 5.49; found C
70.94, H 4.86, N 5.16.
(3aS*,6aS*)-2-Benzyl-4-(difluoromethyl)-6,6a-dihydrocyclo-
penta[c]pyrrole-1,3(2H,3aH)-dione [(±)-34]: White solid (61 %).
M.p. 62–65 °C. Rf = 0.53 (n-hexane/EtOAc, 2:1). 1H NMR (400 MHz,
CDCl3): δ = 2.81–3.03 (m, 2 H, 6-H), 3.49–3.64 (m, 1 H, 6-Ha), 3.95–
4.06 (m, 1 H, 3-Ha), 4.57–4.70 (m, 2 H, benzylic CH2), 6.13–6.19 (m,
1 H, 5-H), 6.19–6.54 (t, J = 55.32 Hz, 1 H, CHF2), 7.24–7.38 (m, 5 H,
CH-Ar) ppm. 13C NMR (125 MHz, CDCl3): δ = 35.1, 42.5, 43.3, 51.5
and 51.5 (3J = 3.46 Hz), 109.1 and 111.0 and 111.0 and 112.9 (1J =
235.34, 1J = 239.60 Hz), 128.1, 128.6, 128.7, 133.6 and 133.8 and
134.0 (2J = 22.98 Hz), 134.2 and 134.3 and 134.3 (3J = 7.06 Hz),
135.5, 175.5, 178.7 ppm. 19F NMR (471 MHz, CDCl3): δ = –121.71
(dd, 2JF,F = 299.62, 2JH,F = 55.16 Hz), –113.29 (dd, 2JF,F = 301.27,
2JH,F = 56.43 Hz) ppm. MS (ESI+): m/z = 278 [M + 1]. C15H13F2NO2
(277.27): calcd. C 64.98, H 4.73, N 5.05; found C 65.32, H 4.48, N
4.76.
CCDC 1814087 [for (±)-12] and 1814088 [for (±)-16] contain the
supplementary crystallographic data for this paper. These data can
be obtained free of charge from The Cambridge Crystallographic
Data Centre.
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